Jiangsu Hengrui Pharmaceuticals (01276): Certain products included in the 2026 National Medical Insurance Catalog

Jiangsu Hengrui Pharmaceuticals (01276) announced that certain of the company's products have been included in the 2026 National Medical Insurance Catalog. Through medical insurance negotiations, Zemrelstat Tablets, Luznorelin Sodium Tablets, and Henggliflozin/Sitagliptin/Metformin Hydrochloride Extended-Release Tablets (II) were included in the National Medical Insurance Catalog for the first time; the new indication for Riconcartuzumab Injection was successfully included in the National Medical Insurance Catalog; Darcilide Ethanesulfonate Tablets successfully renewed and a new indication was included in the National Medical Insurance Catalog; Proline Henggliflozin Tablets, Revenirutamide Tablets, Tegilidine Fumarate Injection, Oteseconazole Capsules, Henggliflozin/Metformin Extended-Release Tablets (I)/(II), Camrelizumab for Injection, and Pregabalin Extended-Release Tablets successfully renewed and remained in the National Medical Insurance Catalog.